Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
Conclusion Collectively, the data suggest IRAB-A acts allosterically on the insulin receptor acting non-competitively with insulin to both activate the receptor and enhance insulin signaling. While IRAB-A produced a decrease in blood glucose in lean mice, the data in DIO mice indicated an exacerbation of insulin resistance; these data were unexpected and suggested the interplay of complex unknown pharmacology. Taken together, this work suggests that IRAB-A may be an important tool to explore insulin receptor signaling and pharmacology.
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Type 2 | Diets | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Insulin | Liver | Nutrition | Obesity | Study | Urology & Nephrology